Trial Profile
Topical tropomysin kinase (TRK) inhibitor as a treatment for inherited CYLD-defective skin tumours (TRAC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Skin tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRAC
- 15 Feb 2019 New source identified and integrated (European Clinical Trials Database EudraCT2014-001342-21)
- 27 Jun 2018 Results published in the JAMA Dermatology
- 03 Apr 2018 New trial record